Samsung Introduces the Industry’s First 5nm Processor Powering the Next Generation of Wearables
10.8.2021 11:08:00 EEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced its new wearable processor, the Exynos W920. The new processor integrates an LTE modem and is the first in the industry to be built with an advanced 5-nanometer (nm) extreme ultra-violet (EUV) process node, offering powerful yet efficient performance demanded by next-generation wearable devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005442/en/
Samsung Introduces the Industry’s First 5nm Processor Powering the Next Generation of Wearables (Graphic: Business Wire)
“Wearables like smartwatches are no longer just a cool gadget to have. They’re now a growing part of our lifestyles to keep you fit, safe and alert,” said Harry Cho, vice president of System LSI marketing at Samsung Electronics. “With the Exynos W920, future wearables will be able to run applications with visually appealing user interfaces and more responsive user experiences while keeping you connected on the go with fast LTE.”
The Exynos W920 packs two Arm® Cortex®-A55 cores for high-performing yet power-efficient processing and an Arm Mali™-G68 GPU that boasts improved CPU performance around 20-percent and ten times better graphics performance than its predecessor. With upgraded cores and improved performance, the Exynos W920 enables faster application launches and more interactive eye-catching 3D graphical user interface (GUI) on a device’s qHD (960×540) display.
Even with the latest features and enhancements, the Exynos W920 comes in the smallest package currently available in the market for wearables with Fan-Out Panel Level Packaging (FO-PLP). The technology incorporates the Exynos W920, power management IC (PMIC), LPDDR4 and embedded multimedia card (eMMC) in the same package using System-in-Package-embedded Package on Package (SiP-ePoP) configuration. The processor’s compact size allows smartwatches to house larger batteries or don sleeker designs.
Always-on-display (AOD) for wearables, especially for smartwatches, is a widely adopted feature as it makes it effortless to take a quick look at the time, notifications, missed calls and more without the need to wake the watch up from sleep mode. Rather than powering up the main CPU, the W920 activates a dedicated low-power display processor, the Cortex-M55, reducing display power consumption under AOD mode compared to its previous Exynos model.
For seamless connected experiences on the go, the Exynos W920 is embedded with a 4G LTE Cat.4 modem as well as a Global Navigation Satellite System (GNSS) L1 for tracking speed, distance and elevation during outdoor activities.
The Exynos W920 supports a new unified wearable platform Samsung built jointly with Google, and will be first applied to the upcoming Galaxy Watch model.
For more information about Samsung’s Exynos products, please visit http://www.samsung.com/exynos.
# # #
* Editor's Note: Actual performance may vary depending on device and user environment.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005442/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)89-45578-1000
Email: sseg.comm@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom